Torcetrapib
| CAS No. | 262352-17-0 | Cat. No. | BCP27677 |
| Name | Torcetrapib | ||
| Synonyms | CP-529414; CP529414; CP 529414; CP-529,414; CP529,414; CP 529,414; | ||
| Formula | C26H26F9N2O4 | M. Wt | 603.49 |
| Description | Torcetrapib, also known as CP-529,414 was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib. Torcetrapib acts (as a CETP inhibitor) by inhibiting cholesterylester transfer protein (CETP), which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels and reduces LDL levels. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | CETP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.